These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The case for combination chemotherapy in the treatment of advanced ovarian cancer. Ozols RF J Clin Oncol; 1985 Nov; 3(11):1445-7. PubMed ID: 3932603 [No Abstract] [Full Text] [Related]
24. Management of recurrent ovarian carcinoma. Ang PT; Kavanagh J Am J Clin Oncol; 1989 Jun; 12(3):269-72. PubMed ID: 2543208 [No Abstract] [Full Text] [Related]
25. [Treatment of advanced ovarian cancer]. de Gramont A; Krulik M; Pigne A; Brissaud P; Sirinelli A; Hubert D; Zylberait D; Debray J Sem Hop; 1984 Mar; 60(14):957-60. PubMed ID: 6326283 [TBL] [Abstract][Full Text] [Related]
26. Cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD) as second-line chemotherapy for ovarian adenocarcinoma. Piver MS; Lele S; Barlow JJ Cancer Treat Rep; 1981; 65(1-2):149-51. PubMed ID: 6784921 [TBL] [Abstract][Full Text] [Related]
27. Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer. Bruckner HW; Cohen CJ; Goldberg JD; Kabakow B; Wallach RC; Deppe G; Reisman AZ; Gusberg SB; Holland JF Am J Obstet Gynecol; 1983 Mar; 145(6):653-8. PubMed ID: 6402934 [TBL] [Abstract][Full Text] [Related]
32. Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine. Razis DV; Poulakou E; Petounis A; Papadimitriou G; Kosmides P; Delides G Oncology; 1982; 39(4):205-8. PubMed ID: 6806735 [TBL] [Abstract][Full Text] [Related]
33. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Vriesendorp R; Kooyman CD; van Lindert AC; Hamerlynck JV; van Lent M; van Houwelingen JC Lancet; 1984 Sep; 2(8403):594-600. PubMed ID: 6147640 [TBL] [Abstract][Full Text] [Related]
34. Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report. Ehrlich CE; Einhorn L; Williams SD; Morgan J Cancer Treat Rep; 1979 Feb; 63(2):281-8. PubMed ID: 376134 [No Abstract] [Full Text] [Related]
37. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer. Levin L; Hryniuk W Semin Oncol; 1987 Dec; 14(4 Suppl 4):12-9. PubMed ID: 3120317 [TBL] [Abstract][Full Text] [Related]
38. Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma. Kane R; Harvey H; Andrews T; Bernath A; Curry S; Dixon R; Gottlieb R; Kukrika M; Lipton A; Mortel R; Ricci J; White D Cancer Treat Rep; 1979 Feb; 63(2):307-9. PubMed ID: 109201 [TBL] [Abstract][Full Text] [Related]
39. HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification. Coleman M; Pasmantier MW; Silver RT Cancer; 1985 May; 55(10):2342-7. PubMed ID: 3921228 [TBL] [Abstract][Full Text] [Related]
40. The treatment of advanced stage ovarian carcinoma with a combination of chemotherapy, radiotherapy, and radiosensitizer: report of a pilot study from the National Cancer Institute. Lichter AS; Ozols RF; Myers CC; Ostechega Y; Young RC Int J Radiat Oncol Biol Phys; 1987 Aug; 13(8):1225-31. PubMed ID: 3112047 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]